Navigation Links
NOVAVAX to Present H1N1 VLP Influenza Vaccine Clinical Data at 7th World Health Organization (WHO) Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials
Date:2/9/2011

ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Gregory Glenn, Chief Medical Officer of Novavax, will be presenting safety and immunogenicity data from its pivotal 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico, at the invitation-only 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting is being held February 17-18, 2011 at the WHO headquarters in Geneva, Switzerland where Dr. Glenn will be part of a session entitled: "Pandemic and Potentially Pandemic Vaccines Developed Using New Technologies."  Dr. Glenn's presentation is entitled: "Rapid Response during the 2009 (H1N1) Pandemic in Mexico with an Influenza VLP Vaccine." The presentation will be available at www.novavax.com under the Investors/Events tab after the event.

About Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs it's cutting edge technology to create next generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary VLP technology and unique disposable system enables rapid vaccine development and production where and when it's needed, worldwide. For more information about Novavax, please visit www.novavax.com.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... -- Robert G. Szewc, M.D., is recognized by Continental Who,s ... his contributions to the Medical field.      ... practice of Kidney and Hypertension Specialists, which specializes in ... He has worked in this position since 2002, and ... as expertise in kidneys, hypertension, chronic disease and anemia, ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... 2017 , ... SABRE is pleased to announce the ... a graduate student from Sonora, California, who will begin her studies this fall ... in Miami, Florida, was selected from a pool of more than 50,000 applicants ...
(Date:9/22/2017)... ... September 22, 2017 , ... TopConsumerReviews.com recently awarded their ... that helps promote pancreatic health and regulate blood sugar levels . , ... can have negative side effects, and with the changes in today’s healthcare industry, ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Fruit of the Spirit: “Love””: ... nature that God has created. “Fruit of the Spirit: “Love”” is the creation of ... devoted wife and mother of five. Halimah is an avid writer, her inspiration for ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global Lyme Alliance (GLA), the ... and awareness, today announced the appointment of Timothy J. Sellati, Ph.D. as its ... more than 20 years of research experience with Lyme and other tick-borne diseases. ...
(Date:9/21/2017)... IL (PRWEB) , ... September 21, 2017 , ... SABRE ... to run from September 11 to the end of November. , The Chicago, Illinois, ... to their community and teach them about the ease of taking their personal safety ...
Breaking Medicine News(10 mins):